Hey Min Lee, Van Morris, MD, Stefania Napolitano, MD, and Scott Kopetz, MD, PhD
In this article, we review the characteristics of the BRAF mutation and the evolving strategies for managing BRAF-mutant metastatic colorectal cancer.
Margaret Von Mehren, MD
Dr. von Mehren discusses current considerations and challenges in the management of patients with soft tissue sarcoma, as well as recent clinical trial data.
FoundationOne®CDx analyzes all recommend genomic biomarkers for solid tumors, including companion diagnostic indications with direct paths to therapy. This one test can help guide therapy selection and clinical trial options for more patients.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
Hey Min Lee, Van Morris, MD, Stefania Napolitano, MD, and Scott Kopetz, MD, PhD
Margaret Von Mehren, MD
